Summary: The Next Drug

Robert Cheng is 69, carries the highest-risk APOE4/APOE4 genotype for Alzheimer’s, and is sitting at the kitchen table with his wife Diane and an informed consent document for a Phase III anti-tau trial 140 miles from their home. Their daughter Lisa is on speaker from Seattle. She has one question nobody at the medical center answered: “What if it works and you can’t afford it afterward?”

The question requires the full picture. The first generation of Alzheimer’s therapeutics, lecanemab and donanemab, are FDA-approved and modestly effective. Lecanemab slowed cognitive decline by approximately 27 percent over eighteen months. Donanemab slowed it by roughly 35 percent among patients who achieved amyloid clearance. These are real effects. They are not cures and they are not stabilization. They slow the rate of decline at a cost of $26,500 per year, with significant side effect risk, particularly for APOE4 carriers like Robert. The research community now understands what these drugs confirmed: amyloid is one part of the pathological process. Tau tangles, neuroinflammation, synaptic loss, and vascular changes each contribute independently. Removing amyloid helps. It does not stop the disease.

The second generation targets the rest. Anti-tau therapies are in Phase II and Phase III trials, with primary results expected within one to two years. The biology is promising. The clinical translation is unproven at scale. Robert’s trial is one of the programs that will produce the answer.

GLP-1 receptor agonists, the class that includes semaglutide, are in clinical trials for cognitive protection. The EVOKE trial tests semaglutide directly in patients with early Alzheimer’s. If results are positive, the implications differ from every other drug in this piece. Semaglutide is already approved, already manufactured at scale, and already prescribed to millions. The path from positive results to availability would be measured in months, not the decade a novel biologic requires. The cost and access picture would be better, though not solved.

Neuroinflammation therapies and combination approaches represent the longer horizon. The oncology model of attacking multiple pathways simultaneously is being applied to Alzheimer’s, with the logic that single-pathway targeting allows the disease to progress through alternative mechanisms. First combination trials are in early stages. Results are years away.

Robert’s specific trial involves biweekly infusions for eighteen months, MRI monitoring, cognitive testing, and a one-in-three chance of receiving placebo. The 280-mile round trip, 26 times per year, plus monitoring visits, is a practical burden he and Diane have budgeted for. What participation provides is access to a potentially effective treatment not otherwise available, protocol-driven monitoring, and the knowledge that his data will inform every family that follows.

Lisa’s question has an honest answer: the pipeline and the access system are separate problems. Novel biologics follow the pricing model that produced lecanemab’s $26,500. If a repurposed GLP-1 drug proves effective, the pricing picture changes because manufacturing infrastructure already exists. But neither answer is fully reassuring. The pipeline is advancing with genuine momentum. The access system has not kept pace.

Robert picks up the pen. He signs the consent document. Lisa says she will drive down for his first infusion.

Read the full article on BlueMirror.life.